Entera Bio (ENTX) Cash from Financing Activities (2021 - 2026)

Entera Bio (ENTX) has 6 years of Cash from Financing Activities data on file, last reported at $130000.0 in Q1 2026.

• Quarterly Cash from Financing Activities fell 99.03% year-over-year to $130000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $503000.0 (down 97.17% YoY) and the FY2025 annual result came in at $13.7 million, up 206.3% from the prior year.
• Cash from Financing Activities eased to $130000.0 in Q1 2026, from $174000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $13.3 million in Q1 2025 to a low of -$51000.0 in Q2 2025.
• A 5-year average of $2.0 million and a median of $152000.0 in 2025 frame the typical range for Cash from Financing Activities.
• The widest YoY moves for Cash from Financing Activities: up 44356.67% in 2025, down 104.19% in 2025.
• Tracing ENTX's Cash from Financing Activities over 5 years: stood at $13000.0 in 2022, then jumped by 46292.31% to $6.0 million in 2023, then tumbled by 46.66% to $3.2 million in 2024, then sank by 94.59% to $174000.0 in 2025, then dropped by 25.29% to $130000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $130000.0 (Q1 2026), $174000.0 (Q4 2025), and $250000.0 (Q3 2025), per Business Quant data.